Sõti Csaba, Nagy Enikõ, Giricz Zoltán, Vígh László, Csermely Péter, Ferdinandy Péter
Department of Medical Chemistry, Semmelweis University, Budapest, Hungary.
Br J Pharmacol. 2005 Nov;146(6):769-80. doi: 10.1038/sj.bjp.0706396.
Chaperones (stress proteins) are essential proteins to help the formation and maintenance of the proper conformation of other proteins and to promote cell survival after a large variety of environmental stresses. Therefore, normal chaperone function is a key factor for endogenous stress adaptation of several tissues. However, altered chaperone function has been associated with the development of several diseases; therefore, modulators of chaperone activities became a new and emerging field of drug development. Inhibition of the 90 kDa heat shock protein (Hsp)90 recently emerged as a very promising tool to combat various forms of cancer. On the other hand, the induction of the 70 kDa Hsp70 has been proved to be an efficient help in the recovery from a large number of diseases, such as, for example, ischemic heart disease, diabetes and neurodegeneration. Development of membrane-interacting drugs to modify specific membrane domains, thereby modulating heat shock response, may be of considerable therapeutic benefit as well. In this review, we give an overview of the therapeutic approaches and list some of the key questions of drug development in this novel and promising therapeutic approach.
伴侣蛋白(应激蛋白)是一类重要蛋白质,有助于其他蛋白质形成并维持正确构象,促进细胞在多种环境应激后存活。因此,正常的伴侣蛋白功能是多种组织内源性应激适应的关键因素。然而,伴侣蛋白功能改变与多种疾病的发生有关;因此,伴侣蛋白活性调节剂成为了一个新兴的药物研发领域。抑制90 kDa热休克蛋白(Hsp)90最近成为对抗各种癌症的一种非常有前景的工具。另一方面,已证明诱导70 kDa Hsp70对从大量疾病(如缺血性心脏病、糖尿病和神经退行性变)中恢复有有效帮助。开发与膜相互作用的药物以修饰特定膜结构域,从而调节热休克反应,也可能具有相当大的治疗益处。在本综述中,我们概述了治疗方法,并列出了这种新颖且有前景的治疗方法中药物研发的一些关键问题。